摘要目的 探讨血清miR-29及miR-150对急性肾损伤（AKI）患者预后的预测价值。方法 选取2016-01~2017-12海南省第三人民医院收治的AKI患者126例，根据其28 d的生存情况分为存活组（82例）和死亡组（44例），按AKI分期标准分为AKI 1期（57例）、AKI 2期（40例）、AKI 3期（29例）。采用RT-PCR检测各组血清miR-29及miR-150表达水平，并记录AKI患者确诊时APACHEⅡ评分。应用受试者工作特征（ROC）曲线分析miR-29及miR-150对AKI患者预后评估的价值。采用Pearson相关分析评价AKI患者血清miR-29、miR-150水平与APACHEⅡ评分的相关性。〖HTH〗结果〓〖HTSS〗死亡组血清miR-29（3.14±0.96 vs. 1.93±0.42）及miR-150（4.26±1.18 vs. 2.05±0.48）表达水平明显高于存活组（t=10.703、15.106，P＜0.001）。AKI 3期血清miR-29（3.34±1.08 vs. 2.19±0.61和1.85±0.34）及miR-150（3.92±1.15 vs. 2.80±0.91和2.55±0.84）表达水平明显高于AKI 2期和AKI 1期（F=5.124、7.825，P＜0.05）。ROC曲线显示，血清miR-29及miR-150预测AKI预后的最佳截断值分别为2.74、3.83，二者联合［AUC（95%CI）：0.918（0.852～0.974）］预测AKI预后的敏感度和特异度较好，分别为93.6%和86.5%。相关分析显示，miR-29水平与miR-150水平呈正相关（r=0.806，P＜0.01），miR-29、miR-150水平与APACHEⅡ评分均呈正相关（r=0.634、r=0.702，P＜0.01）。结论血清miR-29及miR-150表达水平与AKI患者病情严重程度相关，可能成为AKI治疗和预后判断的新靶点。
温莉玲，陈家佳，梁红丽，符明昌. 血清miR-29及miR-150对急性肾损伤患者预后的预测价值[J]. 中国急救医学, 2018, 38(7): 581-585.
Wen Li-ling, Chen Jia-jia, Liang Hong-li, Fu Ming-chang. Prognostic value of serum miR-29 and miR-150 in patients with acute renal injury. Chinese Journal of Critical Care Medicine, 2018, 38(7): 581-585.
［1］Lameire NH, Bagga A, Cruz D, et al. Acute kidney injury: an increasing global concern［J］. Lancet, 2013, 382(9887): 170-179.
［2］Kellum JA, Prowle JR. Paradigms of acute kidney injury in the intensive care setting［J］. Nat Rev Nephrol, 2018, 14(4): 217-230.
［3］Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges［J］. Nat Rev Drug Discov, 2014, 13(8): 622-638.
［4］Kriegel AJ, Liu Y, Fang Y, et al. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury［J］. Physiol Genomics, 2012, 44(4): 237-244.
［5］Ranganathan P, Jayakumar C, Tang Y, et al. MicroRNA-150 deletion in mice protects kidney from myocardial infarction-induced acute kidney injury［J］. Am J Physiol Renal Physiol, 2015, 309(6): F551-F558.
［6］Khwaja A. KDIGO clinical practice guidelines for acute kidney injury［J］. Nephron Clin Pract, 2012, 120(4): c179-c184.
［7］Hershkovitz-Rokah O, Geva P, Salmon-Divon M, et al. Network analysis of microRNAs, genes and their regulation in diffuse and follicular B-cell lymphomas［J］. Oncotarget, 2018, 9(8): 7928-7941.
［8］赵阳, 崔丽艳. microRNA作为急性肾损伤早期诊断生物标志物的研究进展［J］.中华检验医学杂志, 2017, 40(8): 633-636.
［9］Xu L, Qi X, Duan S, et al. MicroRNAs: potential biomarkers for disease diagnosis［J］. Biomed Mater Eng, 2014, 24(6): 3917-3925.
［10］Wang B, Komers R, Carew R, et al. Suppression of microRNA-〖JP〗29 expression by TGF-β1 promotes collagen expression and renal fibrosis［J］. J Am Soc Nephrol, 2012, 23(2): 252-265.
［11］Zhou H, Hasni SA, Perez P, et al. miR-150 promotes renal fibrosis in lupus nephritis by downregulating SOCS1［J］. J Am Soc Nephrol, 2013, 24(7): 1073-1087.
［12］Lorenzen JM, Kielstein JT, Hafer C, et al. Circulating miR-210 predicts survival in critically ill patients with acute kidney injury［J］. Clin J Am Soc Nephrol, 2011, 6(7): 1540-1546.
［13］Wang N, Zhou Y, Jiang L, et al. Urinary microRNA-10a and microRNA-30 d serve as novel, sensitive and specific biomarkers for kidney injury［J］. PLoS One, 2012, 7(12): e51140.
［14］Lorenzen JM, Kaucsar T, Schauerte C, et al. MicroRNA-24 antagonism prevents renal ischemia reperfusion injury［J］. J Am Soc Nephrol, 2014, 25(12): 2717-2729.
［15］Martino F, Lorenzen J, Schmidt J, et al. Circulating microRNAs are not eliminated by hemodialysis［J］. PLoS One, 2012, 7(6): e38269.
［16］宁莉, 魏殿军. 急性肾损伤相关miRNA的研究进展［J］. 山东医药, 2017, 57(14): 110-112.
［17］Banaei S. Novel role of microRNAs in renal ischemia reperfusion injury［J］. Ren Fail, 2015, 37(7): 1073-1079.
